The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.
Kevin W. Song
Disclosure not yet available
Meletios A. Dimopoulos
Disclosure not yet available
Katja C. Weisel
Disclosure not yet available
Philippe Moreau
Disclosure not yet available
Martha Lacy
Disclosure not yet available
Michel Delforge
Disclosure not yet available
Lionel Karlin
Disclosure not yet available
Hartmut Goldschmidt
Disclosure not yet available
Anne Banos
Disclosure not yet available
Albert Oriol Rocafiguera
Disclosure not yet available
Stacie Hudgens
Disclosure not yet available
Zhinuan Yu
Disclosure not yet available
Lars Sternas
Disclosure not yet available
Christian Jacques
Disclosure not yet available
Mohamed H. Zaki
Disclosure not yet available
Jesùs F. San-Miguel
Disclosure not yet available